echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Dig Dis Sci: Delayed initiation of rescue therapy in patients with acute severe ulcerative colitis is associated with prolonged hospital stay

    Dig Dis Sci: Delayed initiation of rescue therapy in patients with acute severe ulcerative colitis is associated with prolonged hospital stay

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, affects more than 3.
    1 million people
    in the United States.
    Acute severe ulcerative colitis (ASUC) is a medical emergency characterized by more than 6 stools per day plus tachycardia > 90 beats per minute (bpm), fever > 37.
    8°C, haemoglobin < 10.
    5 gm/dL, and/or erythrocyte sedimentation rate (ESR) > 30 mm/hour
    , according to Truelove and Witts criteria.
    Severe episodes of IBD often require hospitalization, which has a significant financial cost
    .
    Length of stay (LOS) is often used to measure the efficiency of healthcare facilities, with the average length of stay in the United States being 4.
    5 days
    .
    Patients with IBD have a longer length of hospital stay (mean LOS 5.
    6 days).

    The objective of this study was to identify factors
    that predict prolonged hospitalized LOS in patients with ASUC.

    The researchers performed data analysis
    on all adult ASUC-related hospitalizations at UCSF between July 1, 2014 and December 31, 2017.
    Univariate and multivariate analyses were then performed to determine factor days associated with LOS < 7 days and ≥ 7 days
    .
    Subgroup analyses were performed while excluding patients
    who underwent colectomy during hospitalization.

    The results of the study showed that a total of 95 patients associated with ASUC were hospitalized in this study
    .
    Initial univariate analysis identified the following factors associated with LOS ≥ 7 days (P < 0.
    05): higher maximum heart rate in the first 24 hours, higher C-reactive protein, no biotherapy, and late hospital days for initiation of biotherapy.
    In mixed-model multivariate analyses, hospitalization days with late initiation of biologics were associated with an increased LOS ≥ of 7 days (OR 3.
    1, 95% CI 1.
    2–7.
    56, p=0.
    012).

    This study confirms multiple predictors of longer hospital stay, including factors
    related to disease severity (non-modifiable) and treatment (possibly modifiable).
    Importantly, this study identified biotin treatment status and delayed initiation of biotin therapy in hospitalized patients who ultimately did not require colectomy as predictors
    of longer LOS (≥ 7 days).

     

    Original source:

    Alyssa Caplan.
    et al.
    Delayed Initiation of Rescue Therapy Associated with Increased Length of Stay in Acute Severe Ulcerative Colitis.
    Digestive Diseases and Sciences.
    2022.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.